LONA Positive Sentiment
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Thursday, December 7, 2023 BiopharmaWatch Research 1 min read Key Takeaway: The ELAINE 2 study is an open-label, phase II trial investigating the efficacy of lasofoxifene combined with abemaciclib in women with metastatic ER+/HER2- breast cancer who have an ESR1 mutation. This study targets patients who have experienced disease progression after previous therapies. The multicenter design aims to provide comprehensive data on this treatment approach.
Full Press Release Details
[vc_row row_height_percent=”0″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”119084″ css=”.vc_custom_1762991626218{margin-top: 90px !important;margin-bottom: 90px !important;}”][vc_column width=”1/1″][vc_column_text uncode_shortcode_id=”107727″]
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
[/vc_column_text][vc_column_text uncode_shortcode_id=”115542″] View Publication [/vc_column_text][/vc_column][/vc_row]